Min-Feng Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Min-Feng Chen has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Cong Luo
Department of Urology, Xiangya Hospital, Central South University, Changsha City, People’s Republic of China
2 shared publications - Xiong-Bing Zu
Department of Urology, Xiangya Hospital, Central South University, Changsha City, People’s Republic of China
2 shared publications - Yi Cai
Department of Urology, Xiangya Hospital, Central South University, Changsha, China
2 shared publications - Bing Shi
Department of Urology, Xiangya Hospital, Central South University, Changsha City, People’s Republic of China
1 shared publication - Chen Chen
Children’s Medical Center, Xiangya Hospital, Central South University, Changsha, China
1 shared publication - Jun Ning
Department of Urology, Xiangya Hospital, Central South University, Changsha City, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 23 July 2022
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 17 (1) , 1-9
Renal phenotypes correlate with genotypes in unrelated individuals with tuberous sclerosis complex in China
Purpose: To explore the relationship between the genotype and renal phenotype in a Chinese cohort and guide clinical decision-making for treating tuberous sclerosis complex (TSC).Materials and methods: We reviewed 173 patients with definite TSC at three centers in China from September 2014 to September 2020. All the patients underwentTSC1andTSC2genetic testing as well as renal phenotypic evaluation. All analyses were performed using the SPSS software, version 19.0, with a cut-offPvalue of 0.05 considered statistically significant.Results: We identified variants in 93% (161/173) cases, including 16%TSC1and 77%TSC2variants. Analysis of the relationship between the genotype and renal phenotype, revealed that those withTSC2variants were more likely to develop severe renal AML (> 4) (P = 0.044). In terms of treatment,TSC2variants were more likely to undergo nephrectomy/partial nephrectomy (P = 0.036) and receive mTOR medication such as everolimus (P < 0.001). However, there was no significant difference between the two groups in terms of their response to the everolimus treatment.Conclusion: Patients withTSC2variants exhibit more severe renal phenotypes, especially those associated with renal angiomyolipomas (AML), and they often require nephrectomy/partial nephrectomy or mTOR medication. Detection of the genotype is helpful in TSC management.
- 23 July 2022
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 17 (1) , 1-9
Open AccessRenal phenotypes correlate with genotypes in unrelated individuals with tuberous sclerosis complex in China
Purpose: To explore the relationship between the genotype and renal phenotype in a Chinese cohort and guide clinical decision-making for treating tuberous sclerosis complex (TSC).Materials and methods: We reviewed 173 patients with definite TSC at three centers in China from September 2014 to September 2020. All the patients underwentTSC1andTSC2genetic testing as well as renal phenotypic evaluation. All analyses were performed using the SPSS software, version 19.0, with a cut-offPvalue of 0.05 considered statistically significant.Results: We identified variants in 93% (161/173) cases, including 16%TSC1and 77%TSC2variants. Analysis of the relationship between the genotype and renal phenotype, revealed that those withTSC2variants were more likely to develop severe renal AML (> 4) (P = 0.044). In terms of treatment,TSC2variants were more likely to undergo nephrectomy/partial nephrectomy (P = 0.036) and receive mTOR medication such as everolimus (P < 0.001). However, there was no significant difference between the two groups in terms of their response to the everolimus treatment.Conclusion: Patients withTSC2variants exhibit more severe renal phenotypes, especially those associated with renal angiomyolipomas (AML), and they often require nephrectomy/partial nephrectomy or mTOR medication. Detection of the genotype is helpful in TSC management.
- Top Cited PapersOpen Access
- 4 March 2022
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 17 (1) , 1-16
Perfect match: mTOR inhibitors and tuberous sclerosis complex
Tuberous sclerosis complex (TSC) is an autosomal dominant syndrome that presents with diverse and complex clinical features and involves multiple human systems. TSC-related neurological abnormalities and organ dysfunction greatly affect the quality of life and can even result in death in patients with TSC. It is widely accepted that most TSC-related clinical manifestations are associated with hyperactivation of the mammalian target of rapamycin (mTOR) pathway caused by loss‑of‑function mutations in TSC1 or TSC2. Remarkable progress in basic and translational research has led to encouraging clinical advances. Although mTOR inhibitors (rapamycin/everolimus) demonstrate great potential in TSC management, two major concerns hamper their generalized application. One is the frequent manifestation of adverse events, such as stomatitis, infections, and menstrual disorders; and the other is the poor response in certain patients. Thus, indicators are required to effectively predict the efficacy of mTOR inhibitors. Herein, we have summarized the current utilization of mTOR inhibitors in the treatment of TSC and focused on their efficacy and safety, in an attempt to provide a reference to guide the treatment of TSC.
- 4 March 2022
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 17 (1) , 1-16
Top Cited PapersOpen AccessPerfect match: mTOR inhibitors and tuberous sclerosis complex
Tuberous sclerosis complex (TSC) is an autosomal dominant syndrome that presents with diverse and complex clinical features and involves multiple human systems. TSC-related neurological abnormalities and organ dysfunction greatly affect the quality of life and can even result in death in patients with TSC. It is widely accepted that most TSC-related clinical manifestations are associated with hyperactivation of the mammalian target of rapamycin (mTOR) pathway caused by loss‑of‑function mutations in TSC1 or TSC2. Remarkable progress in basic and translational research has led to encouraging clinical advances. Although mTOR inhibitors (rapamycin/everolimus) demonstrate great potential in TSC management, two major concerns hamper their generalized application. One is the frequent manifestation of adverse events, such as stomatitis, infections, and menstrual disorders; and the other is the poor response in certain patients. Thus, indicators are required to effectively predict the efficacy of mTOR inhibitors. Herein, we have summarized the current utilization of mTOR inhibitors in the treatment of TSC and focused on their efficacy and safety, in an attempt to provide a reference to guide the treatment of TSC.